Lennar Corporation (LEN) Stock Price Today
Aura AI Summary
Key Stats
- $21.19BMARKET_CAP
- -VOLUME
- Consumer CyclicalSECTOR
- $142.40FIFTY_TWO_WEEK_HIGH
- $82.30FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $25.07BENTERPRISE_VALUE
- 2.27%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Lennar Corporation (LEN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Lennar Corporation has traded between a low of $82.3 and a high of $142.4, highlighting its annual price range. Buy and sell Lennar Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Most Recent News
Taiwan Freedom Project launches series to highlight Taiwan's geopolitical importance and counter CCP narratives.
The Taiwan Freedom Project has released a special 32-page section in The Washington Times titled "Why Taiwan Matters, Now More Than Ever," emphasizing Taiwan's critical geopolitical role and the threats it faces from China. The publication features b...

Alvotech's Celtic Lux Holdings pledges over 95 million shares and warrants in a June 26 transaction.
Alvotech announced that Celtic Lux Holdings S.a. r.l., formerly Alvogen Lux Holdings, pledged 88,940,619 shares and 7,007,321 Swedish warrants equivalent to shares on June 26. This transaction was reported to Luxembourg's financial regulator CSSF. Th...

Class action filed against Insulet over alleged product safety and disclosure issues, stock drops follow.
A class action lawsuit has been filed against Insulet Corporation by investors who bought shares between February 2025 and May 2026. The suit alleges Insulet misled investors by failing to disclose defects in its manufacturing controls that posed saf...
